Articles tagged with Cancer Medication
A systematic review and meta-analysis of published studies found strong evidence that e-cigarette use increases the risk of subsequent cigarette smoking among adolescents and young adults. E-cigarettes may mimic smoking behavior through similar hand-to-mouth movements and contain nicotine, potentially enhancing addiction.
A recent study by researchers at Case Western Reserve University has discovered that injecting potato virus particles into melanoma tumors activates an anti-tumor immune response, halting tumor progression. Co-administering the nanoparticles with chemotherapy drugs yields the most potent benefit.
Researchers developed micro-cubes that can sponge up a hydrophobic anti-cancer drug and deliver it to cancer cells, showing increased potency against liver cancer cells and reduced harm to normal liver cells. The cubes retain their shape and release the drug in response to higher redox potentials found in cancer cells.
Researchers at Duke University Medical Center have discovered a new antibody that can restore the effectiveness of chemotherapy rituximab in leukemia patients with natural resistance. The study found that adding the antibody to rituximab increased cancer cell death by 45% in five out of 11 patients.
Researchers found that distinct variations in protein expression levels, rather than genetic alterations, are linked to response or resistance to immunotherapy drugs. The study identified specific genes and proteins associated with tumor growth and immune evasion, paving the way for new therapeutic targets.
A new study found that nearly three-quarters of women relied on a support network to discuss their treatment options and attend appointments. Larger support networks were associated with more deliberation about treatment, suggesting patients are thinking through pros and cons.
Researchers found that DNA methylation analysis can predict cancer versus normal tissue with over 95% accuracy, identifying metastases with 97% correctness. This method could improve outcomes by providing more accurate diagnoses, particularly for indolent or aggressive tumors.
A British exit from the EMA could delay the availability of new medicines to the UK market, according to an independent health economist. The author argues that removal from the EMA would jeopardize access not only to emerging treatments but also cheaper off-brand counterparts once patents expire.
Scientists harness immune system's detection of cancer proteins to improve treatment, showing 20% complete response in preclinical melanoma models. The 'sticky' nanoparticles work synergistically with immunotherapy drugs to increase immune cell response.
Researchers found that savolitinib, a MET inhibitor, showed significant tumor shrinkage and stable disease in 18% of patients with MET-driven papillary renal cell carcinoma. The treatment was generally well-tolerated, with longer time to cancer progression in MET-driven tumors compared to those without the abnormality.
A new study shows that immunotherapy nivolumab improves quality of life for patients with advanced head and neck cancer, while traditional chemotherapies cause decline in quality of life from the start of treatment. The drug sparks the immune system into action against cancers, greatly increasing survival rates.
A study published in Cell Chemical Biology highlights the need for new treatment approaches for treatment-resistant prostate cancer. Researchers found that effective steroidal anti-androgens share common metabolic activities, suggesting a potential strategy to improve efficacy.
A team of researchers at McMaster University has identified a unique feature of cancer stem cells that can be exploited to kill the deadly cells. By understanding this feature, they discovered an important protein called Sam68, which allows existing drugs to work on cancer cells, causing them to die.
A patent study has identified chemically modified marine-derived microtubule-targeting agents with significant antiproliferative potency against a wide range of cancers. These drugs offer potential for overcoming multidrug resistance and improving cancer therapy outcomes.
Researchers found gilteritinib, an FLT3 inhibitor, to be a well-tolerated treatment that led to frequent clinical responses in patients with the FLT3 gene mutation, a common cause of relapsed leukemia. The drug showed promising results in a first-in-human study, with response rates tracking with the degree of FLT3 inhibition.
The game, developed by Imperial College London researchers, challenges players to dock molecules into proteins while learning about the science. The 3D version, BioBlox3D, aims to crowdsource protein docking problems through citizen science challenges.
A new three-in-one blood test developed by researchers at the Institute of Cancer Research can pick out men with advanced prostate cancer who are likely to benefit from treatment with PARP inhibitors. The test detects early signs of resistance and monitors cancer's evolution over time, allowing for timely adjustments to treatment.
Researchers developed a new drug delivery platform that uses ultrasound waves to trigger the dispersal of chemotherapy-containing nanoparticles precisely at tumor sites. The platform resulted in a two-fold increase in targeting efficacy and a dramatic reduction in both tumor size and drug-related toxicity.
The Pew Charitable Trusts has announced the 2017 class of Pew-Stewart Scholars for Cancer Research, five early-career scientists conducting groundbreaking research on finding cures for cancer. The scholars will receive flexible funding to invest in their work and investigate promising avenues to slow or stop cancer development.
New research from the University of Pennsylvania School of Medicine finds that lenvatinib improves overall survival rates in older thyroid cancer patients who are resistant to standard radioiodine treatment. The drug is well-tolerated and has a significant impact on patient outcomes.
Children as young as 8 years old can reliably assess experimental therapy effects on symptoms and quality of life. Self-reported patient outcomes could be a new endpoint in clinical trials, enabling clinicians to better manage side effects.
A new study suggests that the experimental drug GGTI-2418 can block a specific protein from degrading another protein that helps kill cancer cells. This discovery has important implications for treating cancers with defective PTEN, as it may allow for a combination of inhibitors to target multiple pathways involved in tumor growth.
Cancer researchers at GW Cancer Center investigate how mantle cell lymphoma cells develop resistance to targeted therapy Ibrutinib. They found that the cells adapt by activating alternative pathways, such as PI3K-AKT-mTOR, allowing them to continue progressing.
A team of researchers has discovered a potential treatment for Duchenne muscular dystrophy by repurposing a compound originally developed to treat cancer. The compound, SU9516, works by boosting muscle repair and regeneration in affected muscles.
Researchers challenge existing understanding of MLL-translocation leukemia by finding that MLL2, not MLL, is the most appropriate target for drugs. The study shows that silencing wildtype MLL has no effect on disease development, but combining it with MLL2 knockout leads to significant reduction in leukemia.
Researchers identified a biomarker that better categorizes patients who would respond to FGFR inhibitors, improving clinical trial design. Combining FGFR inhibitors with chemotherapy has the potential to improve treatment outcomes.
A Phase III trial shows that peptide-receptor radionuclide therapy significantly improves patient wellbeing, particularly in advanced midgut neuroendocrine tumors. Lutathera treatment provided more relief for patients than high-dose octreotide, with improved quality-of-life metrics and fewer side effects.
Researchers at H. Lee Moffitt Cancer Center identify novel inhibitor (R)-9bMS that targets epigenetic modification of the androgen receptor gene, blocking growth in resistant prostate cancer cells. The discovery offers a new therapeutic option for castration-resistant prostate cancer patients who do not respond to enzalutamide.
Researchers have discovered a way to increase the effectiveness of doxorubicin in treating colon cancer while minimizing its toxic side effects. The new combination therapy uses aldose reductase inhibitors to block oxidative signals that drive cancer growth.
A new strategy for treating glioblastoma, a difficult-to-treat brain tumor, has shown promising results in mice by combining medications that disable two proteins. This approach could potentially extend or save the lives of patients diagnosed with this lethal form of cancer.
Researchers at SLU have identified a key molecular pathway driving cancer-related bone pain and discovered a potential solution with an existing drug. A new study provides hope for patients suffering from this debilitating condition.
The ALEX trial demonstrates alectinib's superiority over crizotinib as first-line therapy for ALK-positive non-small cell lung cancer, with improved progression-free survival and brain metastasis outcomes. Alectinib achieved a 53% reduction in progression risk and 68.4% one-year progression-free rate compared to crizotinib.
Researchers discovered that cancer cells sense their environment's stiffness, slowing down movement with specific drug combinations. This finding has potential for regenerative medicine applications, such as improving adult stem cell therapy.
The Warren Alpert Foundation Prize recognizes scientists who elucidated fundamental mechanisms in cancer's ability to evade immune surveillance. The five honorees' work led to the development of effective immune therapies for several types of cancer, turning the tide in the global fight against cancer.
Scientists have applied iPANDA, a novel approach for analyzing high-throughput transcriptomic datasets, to identify the earliest signaling harbingers of malignant transition in OSCC. The study reveals that dysregulation of these signaling networks occurs even before precancerous cells invade and acquire malignant potential.
Dasatinib demonstrated significant benefits in a phase II clinical trial for pediatric chronic myeloid leukemia (CML), with 75% of patients experiencing progression-free survival after treatment. The study also showed minimal toxicities and improved quality of life for patients.
A new study by SWOG found that publicly funded cancer trials have saved over 3.34 million years of life, with a estimated cost of $125 per life year gained. The study analyzed data from 193 Phase III randomized trials and estimated the cumulative life years gained from each trial.
Researchers found that two FDA-approved immunotherapy drugs, dabrafenib and trametinib, are well-tolerated and result in a 50-54% response rate among patients with advanced BRAF-mutated papillary thyroid cancer. This breakthrough could change the standard of care for this rare but aggressive form of thyroid cancer.
A web-based tool enables patients to report symptoms in real time, triggering alerts to clinicians, resulting in a median survival of 5 months longer. Patients experience improved quality of life and are able to tolerate chemotherapy longer.
A new cancer medicine, larotrectinib, has demonstrated compelling evidence for treating a range of advanced cancers. The therapy, which targets TRK fusion proteins, resulted in responses in 76% of patients across 17 different types of cancer. After 12 months of treatment, 79% of responding patients remained progression-free.
The immunotherapy drug pembrolizumab has been shown to shrink tumors in patients with metastatic triple negative breast cancer, regardless of prior treatment. In a Phase II clinical trial, the drug demonstrated activity in both PD-L1-positive and -negative tumors.
Researchers have created a method to produce P450 enzymes in bacterial cell factories, which are also involved in the biosynthesis of active ingredients used in cancer drugs. The process could facilitate large-scale production of these enzymes, allowing for more efficient treatment of diseases such as cancer and psoriasis.
A study published in Journal of Palliative Medicine suggests that patients with life-limiting illnesses may not feel abandoned if their doctor wants to discontinue statin medications. Most patients reported benefits from stopping statins, including improved quality of life and reduced medication costs.
A study found that combining therapies targeting polyADP ribose polymerase (PARP) and mitogen-activated protein kinase (MEK) inhibitors showed promise in treating RAS-mutant cancers. The combination therapy was effective in multiple tumor models, regardless of mutations in tumor suppressor genes.
Researchers from Fred Hutch Cancer Center are showcasing promising new treatments for various types of cancer, including pancreatic cancer, Merkel cell carcinoma, and early-stage breast cancer. The findings suggest that experimental drugs, triple immunotherapy, and novel sarcoma vaccines may provide extended progression-free survival p...
A recent study by the UNC Lineberger Comprehensive Cancer Center found that physicians paid by pharmaceutical companies had higher odds of prescribing their drugs for two types of cancer. The researchers analyzed prescription patterns for Medicare patients with metastatic kidney cancer and chronic myeloid leukemia, and found a consiste...
Researchers at Stanford University have created a computer algorithm called MiSL that identifies pairs of cancer-associated genes, known as synthetic lethals, which could be targeted with drugs. This approach aims to develop less-toxic treatments for various cancers by pinpointing the genetic partners of well-known cancer mutations.
The university will investigate genetic determinants of Barrett's Esophagus and esophageal adenocarcinoma, developing a new molecular marker for detection. The research aims to improve non-invasive diagnostic approaches and treatment of esophageal cancer.
Scientists at Tomsk Polytechnic University have developed a radiopharmaceutical for advanced cancer identification, using the technetium-99 isotope. The medication targets cancer receptors and can accurately determine tumor size and location.
Scientists at Rice University have developed analogs of potent anti-tumor agents, which show superior properties and exhibit potent cytotoxicities against certain cancer cells. The new compounds were tested on kidney cancer and human uterine sarcoma cell lines, including a drug-resistant cell line.
Researchers from ETH Zurich have defined the three-dimensional structure of ABCG2, a human multi-drug transporter. The protein recognizes and transports over 200 substances, including toxins and medications, making it a double-edged sword in cancer treatment and drug development.
Researchers discovered a biochemical signaling process that causes densely packed cancer cells to break away and spread the disease. The combined use of two existing drugs disrupts this process, significantly slowing cancer's tendency to travel.
Researchers discovered that a molecule called PD-L1 can mask pain by suppressing nociceptive neuron activity via PD-1. This finding could lead to the development of predictive tests and treatments for pain, as well as new ways to assess immunotherapy treatment efficacy.
Scientists have created a library of 308 compounds to test drug combinations for new therapies. A study found a synergy between flutamide and phenprocoumon that efficiently killed prostate cancer cells, targeting the androgen receptor. The CLOUD library is ideal for discovering new applications for approved active ingredients.
A new study confirms high-ventilation cigarettes have no health benefits and likely contributed to the rise of lung adenocarcinoma. Researchers call for immediate action from the FDA to regulate or ban the use of ventilation holes.
Researchers have discovered that directly injecting a tumor suppressor activator into a cancer can increase tumor destruction, while reducing toxic side effects. The agent, nutlin-3a, activates the natural p53 gene, which helps immune cells target and kill cancer cells.
A new nanofluidic device enables rapid testing of protein drugs produced by living cells, offering continuous monitoring and automated quality control. The system can analyze small protein samples in 30-40 minutes, with potential future miniaturization for real-time point-of-care checks.
A recent study found that a cancer drug called ibrutinib can reduce allergic skin test reactivity by 80-90% in patients with certain types of leukemia and lymphoma. The treatment also showed promise in preventing reactions to common airborne allergens, such as cat dander and ragweed.
A new study by researchers at the University of Southern California reveals that reducing glucose-regulated protein GRP78 can halt pancreatic cancer development and prolong survival. The findings suggest that targeting this protein could lead to a novel approach in treating KRAS-mutation related cancers.
AbeXXa Biologics identifies targets for cancer treatment from thousands of intracellular proteins, potentially resulting in effective immunotherapies for broad patient groups. The company is developing T cell receptor-like antibody-drug complexes to kill tumor cells with low peptide/HLA targets.